– For Immediate Release –
Clinical Research Advantage CEO Recognized as one of Arizona’s Business Leaders
Tempe, Ariz. (December – , 2013) – Clinical Research Advantage (CRA), a company that provides clinical trial solutions for pharmaceutical sponsors and contract research organizations, is excited to announce that the company’s Chief Executive Officer, Mark Hanley, has been featured in the inaugural edition of AZ Business Leaders Magazine. Hanley’s executive profile was featured in the Bioscience category.
In addition to profiling Hanley’s career, the magazine quoted the serial entrepreneur on the best business advice he has received, as well as the best business advice he can offer to up-and-coming business executives and entrepreneurs. “It was an honor to be selected for this publication,” said Hanley. “Arizona has a business community that is growing and thriving, and I am happy to be a part of that. I am excited to see Arizona continue to build upon its success.”
AZ Business Leaders, a publication of AZ Big Media, is an annual publication that profiles local executives in 60 industry categories. Profile candidates are selected by AZ Big Media and asked to share the business principles that have fueled their success and the success of their companies. These prominent local executives have the distinguished combination of experience, vision and influence. The magazine’s website expresses: “These respected leaders guide companies that drive Arizona’s economy. They are the past, present and future of Arizona business.”
About Clinical Research Advantage
Tempe, Ariz.-based Clinical Research Advantage, Inc. (CRA) is the country’s largest wholly owned network of clinical trial sites. CRA works with pharmaceutical companies and contract research organizations to perform clinical trials for pharmaceuticals, vaccines and medical devices. The services provided by CRA allow trial sponsors to bring medical advancements to market quickly and efficiently. Founded in 1992, CRA acquired Radiant Research in 2012 and Comprehensive Clinical Development in 2013. Combined, the companies have successfully completed more than 11,000 clinical trials. For more information, please visit www.crastudies.com.